EquitiesIndia.com

Educational content only. EquitiesIndia.com is not a SEBI-registered Research Analyst or Investment Adviser. Nothing on this site is investment advice or a solicitation to transact in any security. All content and data is historical and for learning purposes only. Full disclaimer →

Healthcare · Drug Manufacturers - Specialty & Generic

Cipla Ltd.

CIPLA

Financials as of(≥90-day lag, SEBI compliant)

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Key metrics

Market Cap

₹99,317 cr

P/E Ratio

21.83x

P/B Ratio

3.18x

ROE

16.9%

ROCE

21.7%

Debt / Equity

0.01x

Net Margin

19.42%

Dividend Yield

106%

EPS

₹65.24

Period

FY2025

Shareholding pattern

As of Latest
Promoter: 30.96%FII: 40.34%Public: 28.70%

Deep-dive pages

Educational content — not investment adviceThis page presents publicly available information about Cipla Ltd. for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing here constitutes investment advice, a recommendation to buy or sell any security, or a solicitation to transact. All financial data shown is sourced from public BSE/NSE filings and is at least 90 days old. Past performance is not indicative of future results. Please consult a SEBI-registered adviser before making any investment decision.